Serum anti-60S ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer.

Abstract

BACKGROUND/AIMS:

Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti- RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer.

METHODS:

We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers.

RESULTS:

Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤ cutoff. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤ cutoff. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤ cut-off. In the multivariate Cox proportional hazard model, serum anti- RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors.

CONCLUSION:

Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

• Authors: Shinichiro Muro, Yasuhiro Miyake, Hironari Kato, Koichiro Tsutsumi, Kazuhide Yamamoto
• Journal: Digestion (Digestion) Vol. 91 Issue 2 Pg. 164-73 ( 2015) ISSN: 1421-9867 [Electronic] Switzerland
• PMID: 25765324 (Publication Type: Journal Article)

Chemical References

• Antibodies
• Biomarkers, Tumor
• Blood Coagulation Factors
• RNA-Binding Proteins
• RPL29 protein, human
• Ribosomal Proteins

Topics

• Adenocarcinoma (blood)
• Adult
• Aged
• Aged, 80 and over
• Antibodies (blood)
• Biomarkers, Tumor (blood)
• Blood Coagulation Factors (immunology)
• Disease Progression
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Male
• Middle Aged
• Pancreatic Neoplasms (blood, mortality)
• Prognosis
• Proportional Hazards Models
• RNA-Binding Proteins
• Retrospective Studies
• Ribosomal Proteins
• Ribosome Subunits, Large, Eukaryotic (immunology)
• Survival Analysis